IceCure ProSense® Achieves 89.4% Renal RFR and 100% Breast Cryoablation Success
ICCM•At ECIO 2026, IceCure presented ICESECRET 5-year data showing 89.4% recurrence-free rate for renal tumors ≤3 cm and 83.9% recurrence-free at median four-year follow-up following ProSense® cryoablation. Independent studies reported 100% no residual disease in 28 early-stage breast tumors at 12 months and 92.9% fibroadenoma volume reduction at one year.
1. ECIO 2026 Presentations
At ECIO 2026, IceCure showcased ProSense® cryoablation across multiple sessions, including the first dedicated breast cryoablation master class which was overbooked, reflecting strong physician demand and hands-on training led by ProSense® experts.
2. ICESECRET Kidney Cancer Results
In the ICESECRET trial, 114 patients with small renal masses (mean size 2.4 cm) underwent 138 ProSense® procedures, achieving 92.5% technical success, an 83.9% recurrence-free rate at a median four-year follow-up and 89.4% for unifocal tumors ≤3 cm, with an average hospital stay of 1.3 days.
3. Breast and Fibroadenoma Efficacy Studies
Independent breast cancer data on 26 patients (28 lesions) showed zero residual disease at six and 12 months with 100% cosmetic satisfaction, while a fibroadenoma cohort of 78 women experienced median volume reductions of 80.6% at six months and 92.9% at 12 months, underscoring ProSense®’s versatility.
